Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eyelid injection shows promise for thyroid eye disease symptoms

NCT ID NCT07471997

Symptom relief Sponsor: Instituto de Oftalmología Fundación Conde de Valenciana Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether injecting triamcinolone acetonide into the eyelid could help people with thyroid eye disease who have a retracted upper eyelid. Fifteen adults received a combination of two injections and were measured one month later. The goal was to see if the eyelid position improved, which could ease eye discomfort and cosmetic concerns.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
triamcinolone acetonide
What this could lead to
If it works, this could offer a simple injection to improve eyelid position and reduce eye discomfort in people with thyroid eye disease.
What could go wrong
This is a very small, early study with only 15 people and no comparison group. Results may not apply to everyone, and the effect may be temporary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

15 people

The number who actually took part.

Started

Jun 2024

Finished

Feb 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female participants aged 18 years or older. * Diagnosis of thyroid eye disease. * Presence of upper eyelid retraction defined as margin reflex distance 1 (MRD1) ≥ 4.5 mm. * Clinical Activity Score (CAS) lower than 3 points. * Ability and willingness to provide written informed consent. Exclusion Criteria: * Previous or current systemic corticosteroid treatment during the study period. * Active thyroid eye disease with Clinical Activity Score (CAS) ≥ 3. * Other causes of eyelid retraction. * Need for urgent surgical management. * Known allergy to triamcinolone acetonide. * Known steroid responders. * Diagnosis of advanced primary or secondary glaucoma according to Hodapp-Parrish-Anderson criteria.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Thyroid eye disease, ted are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

endocrine exophthalmos Graves Ophthalmopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Thyroid eye disease, ted

Contacts and locations

Locations

  • Instituto de Oftalmologia F.A.P. Conde de Valenciana, I.A. P.

    Mexico City, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.